Impact of microsatellite status in early-onset colonic cancer

Simple item page
dc.contributor.authorZaborowski, A.M.
dc.contributor.authorAbdile, A.
dc.contributor.authorAdamina, M.
dc.contributor.authorAigner, F.
dc.contributor.authorD'Allens, L.
dc.contributor.authorAllmer, C.
dc.contributor.authorAlvarez, A.
dc.contributor.authorAnula, R.
dc.contributor.authorAndric, M.
dc.contributor.authorAtallah, S.
dc.contributor.authorBach, S.
dc.contributor.authorBala, M.
dc.contributor.authorBarussaud, M.
dc.contributor.authorBausys, A.
dc.contributor.authorBeggs, A.
dc.contributor.authorBellolio, F.
dc.contributor.authorBennett, M.-R.
dc.contributor.authorBevan, V.
dc.contributor.authorBiondo, S.
dc.contributor.authorBislenghi, G.
dc.contributor.authoret al.
dc.date.issued2022
dc.descriptionAdvance Access Publication Date: 6 May 2022
dc.description.abstractBackground: The molecular profile of early-onset colonic cancer is undefined. This study evaluated clinicopathological features and oncological outcomes of young patients with colonic cancer according to microsatellite status. Methods: Anonymized data from an international collaboration were analysed. Criteria for inclusion were patients younger than 50 years diagnosed with stage I–III colonic cancer that was surgically resected. Clinicopathological features, microsatellite status, and disease-specific outcomes were evaluated. Results: A total of 650 patients fulfilled the criteria for inclusion. Microsatellite instability (MSI) was identified in 170 (26.2 per cent), whereas 480 had microsatellite-stable (MSS) tumours (relative risk of MSI 2.5 compared with older patients). MSI was associated with a family history of colorectal cancer and lesions in the proximal colon. The proportions with pathological node-positive disease (45.9 versus 45.6 per cent; P=1.000) and tumour budding (20.3 versus 20.5 per cent; P=1.000) were similar in the two groups. Patients with MSI tumours were more likely to have BRAF (22.5 versus 6.9 per cent; P,0.001) and KRAS (40.0 versus 24.2 per cent; P=0.006) mutations, and a hereditary cancer syndrome (30.0 versus 5.0 per cent; P,0.001; relative risk 6). Five-year disease-free survival rates in the MSI group were 95.0, 92.0, and 80.0 per cent for patients with stage I, II, and III tumours, compared with 88.0, 88.0, and 65.0 per cent in the MSS group (P=0.753, P=0.487, and P=0.105 respectively). Conclusion: Patients with early-onset colonic cancer have a high risk of MSI and defined genetic conditions. Those with MSI tumours have more adverse pathology (budding, KRAS/BRAF mutations, and nodal metastases) than older patients with MSI cancers.
dc.description.statementofresponsibilityREACCT Collaborative: Alexandra M. Zaborowski ... Hidde Maarten Kroon ... Tarik Sammour ... et al.
dc.identifier.citationBritish Journal of Surgery, 2022; 109(7):632-636
dc.identifier.doi10.1093/bjs/znac108
dc.identifier.issn0007-1323
dc.identifier.issn1365-2168
dc.identifier.orcidKroon, H.M. [0000-0002-8923-7527]
dc.identifier.orcidSammour, T. [0000-0002-4918-8871]
dc.identifier.urihttps://hdl.handle.net/2440/140255
dc.language.isoen
dc.publisherWiley
dc.rights© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved.
dc.source.urihttps://doi.org/10.1093/bjs/znac108
dc.subjectREACCT Collaborative
dc.subject.meshHumans
dc.subject.meshColorectal Neoplasms
dc.subject.meshColonic Neoplasms
dc.subject.meshProto-Oncogene Proteins B-raf
dc.subject.meshPrognosis
dc.subject.meshMicrosatellite Repeats
dc.subject.meshMutation
dc.subject.meshProto-Oncogene Proteins p21(ras)
dc.subject.meshMicrosatellite Instability
dc.titleImpact of microsatellite status in early-onset colonic cancer
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Surgery publications